Copyright: ©Author(s) 2026.
World J Gastroenterol. Jun 14, 2026; 32(22): 117417
Published online Jun 14, 2026. doi: 10.3748/wjg.v32.i22.117417
Published online Jun 14, 2026. doi: 10.3748/wjg.v32.i22.117417
Figure 4 Assessment of tertiary lymphoid structures and their prognostic value stratified by human epidermal growth factor receptor 2 status.
A: Hematoxylin and eosin staining showing the histopathological structure of tertiary lymphoid structures (TLS); B: Immunohistochemistry (IHC) staining for CD20 within the TLS; C: IHC staining for CD21; D: IHC staining for CD4; E: IHC staining for CD8; F: Correlation analysis between TLS abundance (TLS score) and human epidermal growth factor receptor 2 (HER2) expression; G: Forest plot showing subgroup survival analysis comparing overall survival between HER2-positive and HER2-negative patients across clinicopathological factors.
- Citation: Han RY, Wei YK, Liu WN, Wang YM, Song TQ, Tian XD, Xia YR, Chen L, Gong WC. Human epidermal growth factor receptor 2 in combined hepatocellular-cholangiocarcinoma: Prognostic and predictive guide for adjuvant chemotherapy. World J Gastroenterol 2026; 32(22): 117417
- URL: https://www.wjgnet.com/1007-9327/full/v32/i22/117417.htm
- DOI: https://dx.doi.org/10.3748/wjg.v32.i22.117417